复锐医疗科技(01696.HK)附属及复星健康基金就投资天津星魅订A轮投资协议
复锐医疗科技(01696.HK)公布,附属复锐医疗天津作为原股东及A轮投资方,与复星健康基金(苏州)及复星健康基金(天津)以及天津星魅生物科技(目标公司)订立A轮投资协议,内容有关向目标公司累计出资1.09亿元人民币(下同),其中复锐医疗天津同意出资1,000万元。
根据A轮投资协议,於A轮投资完成後,倘目标公司拟发行额外股份以筹集资金,且复星健康基金(苏州)及复星健康基金(天津)拟参与此类融资,则复锐医疗天津亦将认购目标公司的额外股份,并按於A轮投资完成後其於目标公司的持股比例额外出资,惟复锐医疗天津的最高出资额不超过1,036.7万元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.